Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Cambrooke Therapeutics Metabolic Liquids and KetoVie Formulas Are Now OU-D Kosher Approved: The Only Manufacturer with Metabolic and Ketogenic Formula Products Certified

Cambrooke Therapeutics Inc.
Posted on: 01 Nov 18

Cambrooke Therapeutics Inc., a leader in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy, continues to make breakthrough advancements for its customers. Cambrooke’s Glytactin GMP and Actin Amino Acid metabolic formula product lines and Ketogenic liquid formulas for people with intractable epilepsy have been OU-D certified by the Union of Orthodox Jewish Congregations of America (the “Orthodox Union”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181101005199/en/

Cambrooke’s Glytactin GMP and Actin Amino Acid metabolic formula product lines and Ketogenic liquid formulas for people with intractable epilepsy have been OU-D certified by the Union of Orthodox Jewish Congregations of America. (Graphic: Business Wire)

To become OU-D certified, a manufacturer must follow strict ingredient selection and product manufacturing guidelines and regulations. Having proven the purity of its ingredients and rigorous attention to quality in manufacturing, Cambrooke has earned the ability to include the world’s most popular kosher certification, OU-D Kosher, on packaging labels and product literature.

Cambrooke is the only manufacturer of metabolic and ketogenic diet therapy medical foods formulas to have the OU-D Kosher certification. The addition of this kosher certification enables more people to enjoy Cambrooke medical foods that are now proven to have been prepared in accordance to their beliefs. The OU-D emblem on Cambrooke metabolic liquid and KetoVie formula products is the latest demonstration of Cambrooke’s dedication to continually seeking ways to make its medical food products the best in meeting customer needs.

Cambrooke’s OU-D certified Glytactin formulas were designed to help meet the specialized nutritional needs of people with phenylketonuria (PKU), a rare genetic disorder requiring a life-long dietary restriction of all food items with regular dietary protein that contain an amino acid called phenylalanine (Phe). Cambrooke was the first to introduce a family of specialized formulas utilizing a natural source of safe protein and naturally fermented amino acids for these patients. Just prior to earning the OU-D Kosher certification, Cambrooke added new products to the Glytactin PKU family to include options featuring the most purified protein with lowest level of Phe and lowest calorie count.

Cambrooke’s OU-D certified KetoVie formulas are unique, ready-to-drink ketogenic formulas with a patented blend of key ingredients for the dietary management of intractable epilepsy. Cambrooke recently launched a highly innovative KetoVie Peptide product that is unlike any other in this category as it is nutritionally optimized for tube-fed patients and is the only option with a hypoallergenic protein source.

“My team is consistently looking at ways to improve our facility and enhance our products. This is just another step forward in demonstrating the quality of our products and in-house production of advanced nutrition. We are proud to have earned the OU-D kosher certification for these products and will continue to expand our certifications for many more products,” said Steven Depew, Cambrooke’s senior vice president of manufacturing and operations.

About Cambrooke Therapeutics—Founded in 2000, Cambrooke Therapeutics, a proud member of The Ajinomoto Group, is a Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious unmet medical needs. Cambrooke Therapeutics works with physicians and researchers from around the world to develop, test, and commercialize products that are focused on inborn errors of metabolism and intractable epilepsy. More information is available at Cambrooke.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005199/en/

Business Wire
www.businesswire.com

Last updated on: 01/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.